Pacira BioSciences (PCRX) EBIT (2010 - 2026)

Pacira BioSciences' EBIT history runs 17 years deep, the most recent figure standing at $6.9 million for Q1 2026.

• On a quarterly basis, EBIT rose 246.83% year-over-year to $6.9 million in Q1 2026; TTM through Mar 2026 was $24.1 million, a 128.49% increase from a year earlier, with the FY2025 full-year figure at $19.2 million, up 126.16% from the prior year.
• EBIT improved to $6.9 million in Q1 2026 per PCRX's latest filing, from $2.3 million in the prior quarter.
• Across five years, EBIT topped out at $39.9 million in Q2 2023 and bottomed at -$139.5 million in Q3 2024.
• The 5-year median for EBIT is $13.2 million (2024), against an average of $5.9 million.
• Biggest YoY gain for EBIT was 527.43% in 2024; the steepest drop was 887.35% in 2024.
• Year by year, EBIT stood at -$9.9 million in 2022, then surged by 435.27% to $33.2 million in 2023, then fell by 25.52% to $24.7 million in 2024, then plunged by 90.53% to $2.3 million in 2025, then soared by 194.96% to $6.9 million in 2026.
• Per Business Quant, the three latest PCRX EBIT figures stand at $6.9 million (Q1 2026), $2.3 million (Q4 2025), and $6.4 million (Q3 2025).